Date: 2025-11-04Category: Not ApplicableState: Union GovernmentCountry: Europe
Commission Implementing Decision (EU) 2025/2214 of 31 October 2025 not amending a Union authorisation for the biocidal product family HYPO-CHLOR Product Family in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (notified under document C(2025) 7271)
Issued by European Commission
· Directorate-General for Health and Food Safety
**Executive Summary**
This Commission Implementing Decision (EU) 2025/2214, dated October 31, 2025, addresses a request to amend the Union authorization for the biocidal product family ‘HYPO-CHLOR Product Family' under Regulation (EU) No 528/2012. The decision concludes that the authorization should not be amended. This implementing decision takes effect immediately and is addressed to Veltek Associates Inc. Europe.
**Key Points / Main Content**
* **Background:**
* Commission Implementing Regulation (EU) 2023/708 granted Union authorization for the biocidal product family ‘HYPO-CHLOR Product Family' to Veltek Associates Inc. Europe.
* The European Chemicals Agency (ECHA) initially did not recommend authorizing a part of the family (‘meta SPC 1 HYPO-CHLOR 5,25 %') due to lack of efficacy data.
* **Application for Major Change:**
* Veltek Associates Inc. Europe applied for a major change to include ‘meta SPC 1 HYPO-CHLOR 5,25 %', providing efficacy data on aged products with a claimed 18-month shelf life.
* France evaluated the application, providing the applicant the opportunity to comment on the assessment report.
* **Agency Opinion:**
* The BPC adopted an opinion concluding that the efficacy study was not performed with the product for which authorization was sought and therefore the efficacy was not proven.
* The Agency recommended not to amend the authorization of 'HYPO-CHLOR Product Family' to include 'meta SPC 1 HYPO-CHLOR 5,25 %'.
* **Decision:**
* The Commission concurred with the Agency's opinion.
* The authorization of 'HYPO-CHLOR Product Family' should not be amended as a condition laid down in Article 19(1), point (b)(i), of Regulation (EU) No 528/2012 is not fulfilled.
* Implementing Regulation (EU) 2023/708 is not amended.
**Impact Analysis**
**Stakeholder:** Veltek Associates Inc. Europe
**Impact:**
The application for a major change to include 'meta SPC 1 HYPO-CHLOR 5,25 %' in the authorization of 'HYPO-CHLOR Product Family' was not approved.
**Action Required:**
Veltek Associates Inc. Europe must comply with the original terms of the Union authorization granted by Implementing Regulation (EU) 2023/708, which does not include 'meta SPC 1 HYPO-CHLOR 5,25 %'.
Key Entities Referenced
Regulation (EU) No 528/2012: Regulation of the European Parliament and of the Council concerning the making available on the market and use of biocidal products.
Implementing Regulation (EU) No 354/2013: Commission Implementing Regulation on changes of biocidal products authorised in accordance with Regulation (EU) No 528/2012.
HYPO-CHLOR Product Family: The biocidal product family for which a Union authorisation was initially granted and a major change was subsequently applied for.
Implementing Regulation (EU) 2023/708: Commission Implementing Regulation granting a Union authorisation for the HYPO-CHLOR Product Family.
European Chemicals Agency ('the Agency'): The agency responsible for assessing applications related to biocidal products.
Official Journal EN
of the European Union L series
2025/2214 4.11.2025
COMMISSION IMPLEMENTING DECISION(EU) 2025/2214
of 31 October 2025
not amending a Union authorisation for the biocidal product family ‘HYPO-CHLOR Product Family’
in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council
(notified under document C(2025) 7271)
(Only the Dutch text is authentic)
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning
the making available on the market and use of biocidal products(1), and in particular Article 50(2) thereof,
Whereas:
(1) On 20 March 2023, Commission Implementing Regulation (EU) 2023/708(2)granted a Union authorisation, under
authorisation number EU-0028423-0000, to Veltek Associates Inc. Europe (‘the applicant’) for the making available
on the market and use of the biocidal product family ‘HYPO-CHLOR Product Family’. As a result of the initial
assessment, the European Chemicals Agency (‘the Agency’) did not recommend that the authorisation for a part of
the proposed biocidal product family (‘meta SPC 1 HYPO-CHLOR 5,25 %’) applied for by the applicant be granted
because no efficacy data was submitted to demonstrate that products of ‘meta SPC 1 HYPO-CHLOR 5,25 %’ would
still be effective after 6 months of storage. The Commission having considered the Agency’s recommendation did
not grant the authorisation for that part of the biocidal product family.
(2) On 14 July 2023, the applicant submitted to the Agency, in accordance with Article 13(1) of Commission
Implementing Regulation (EU) No 354/2013(3), an application for a major change to the Union authorisation for
the biocidal product family ‘HYPO-CHLOR Product Family’, recorded in the Register for Biocidal Products under case
number BC-KQ087764-07. The proposed change concerned the inclusion of the former ‘meta SPC 1 HYPO-CHLOR
5,25 %’ that was previously applied for by the applicant but not granted, with a claimed shelf life of 18 months for
which efficacy data on aged products were submitted. The application was evaluated by the competent authority of
France (‘the evaluating competent authority’).
(3) On 26 June 2024, the evaluating competent authority gave the applicant the opportunity to provide written
comments on the draft product assessment report and the conclusions of the evaluation of the application for major
change within 30 days, in accordance with Article 13(5), second subparagraph, of Implementing Regulation (EU)
No 354/2013. On 24 July 2024, the applicant submitted comments to the evaluating competent authority. On
6 September 2024, the evaluating competent authority provided responses to those comments.
(4) On 23 September 2024, the evaluating competent authority submitted, in accordance with Article 13(5), first
subparagraph, of Implementing Regulation (EU) No 354/2013, an assessment report and the conclusions of its
evaluation to the Agency.
(1) OJ L 167, 27.6.2012, p. 1, ELI: http://data.europa.eu/eli/reg/2012/528/oj.
(2) Commission Implementing Regulation (EU) 2023/708 of 20 March 2023 granting a Union authorisation for the biocidal product
family ‘HYPO-CHLOR Product Family’ in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the
Council (OJ L 93, 31.3.2023, p. 40, ELI: http://data.europa.eu/eli/reg_impl/2023/708/oj).
(3) Commission Implementing Regulation (EU) No 354/2013 of 18 April 2013 on changes of biocidal products authorised in accordance
with Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L 109, 19.4.2013, p. 4, ELI: http://data.europa.
eu/eli/reg_impl/2013/354/oj).
ELI: http://data.europa.eu/eli/dec_impl/2025/2214/oj 1/2EN
OJ L, 4.11.2025
(5) Prior to the adoption and submission of the Agency’s opinion in accordance with Article 13(7) of Implementing
Regulation (EU) No 354/2013, the applicant was given the opportunity to be involved in the process of the
preparation of the Agency’s opinion. Between 26 September and 27 November 2024, the applicant was informed
about the status of the procedure, provided several written comments during that period in the Register for Biocidal
Products and attended the 53rd meeting of the Biocidal Products Committee of the Agency (‘the BPC’) of
27 November 2024. The applicant acknowledged that the tested product contained a higher concentration of
sodium hypochlorite but argued that that higher concentration was justified based on the fact that sodium
hypochlorite degrades quickly. The tested product contained more sodium hypochlorite than the 5,25 % w/w
sodium hypochlorite content set for ‘meta SPC 1 HYPO-CHLOR 5,25 %’ to try to address the issue of the quick
degradation of the active substance. Contrary to the views of the applicant, the BPC considered that for products
containing unstable active substances, storage stability tests should be conducted on fresh products to ensure their
representativeness.
(6) On 27 November 2024, the opinion on the major change was adopted by the BPC(4). The opinion concludes that as
the efficacy study provided was not performed with the product for which the change of the authorisation was
sought, efficacy has not been proven for the duration of the product’s shelf life. The Agency therefore recommends
not to amend the authorisation of ‘HYPO-CHLOR Product Family’ to include ‘meta SPC 1 HYPO-CHLOR 5,25 %’.
(7) The Commission concurs with the opinion of the Agency that the authorisation of ‘HYPO-CHLOR Product Family’
should not be amended as the condition laid down in Article 19(1), point (b)(i), of Regulation (EU) No 528/2012 is
not fulfilled and the applicant’s application for a major change to its authorisation should therefore not be
accommodated.
(8) Implementing Regulation (EU) 2023/708 should therefore not be amended,
HAS ADOPTED THIS DECISION:
Article 1
Annex II to Implementing Regulation (EU) 2023/708 is not amended.
Article 2
This Decision is addressed to Veltek Associates Inc. Europe, Rozengaard 1940, 8212DT Lelystad, Netherlands.
Done at Brussels, 31 October 2025.
For the Commission
Olivér VÁRHELYI
Member of the Commission
(4) Biocidal Products Committee (BPC) opinion of 27 November 2024 on the major change to the Union authorisation of the biocidal
product family ‘HYPO-CHLOR Product Family’ (ECHA/BPC/452/2024), https://echa.europa.eu/de/opinions-on-union-authorisation.
2/2 ELI: http://data.europa.eu/eli/dec_impl/2025/2214/oj